Barclays Lowers Fortrea (NASDAQ:FTRE) Price Target to $12.00

Fortrea (NASDAQ:FTRE) had its target price decreased by analysts at Barclays from $15.00 to $12.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Barclays‘s price objective indicates a potential upside of 11.94% from the company’s previous close.

Several other equities analysts have also recently issued reports on FTRE. TD Cowen boosted their price objective on shares of Fortrea from $7.00 to $15.00 and gave the company a “hold” rating in a research note on Thursday, January 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fortrea in a research note on Thursday, January 22nd. Evercore set a $25.00 price target on shares of Fortrea and gave the stock an “outperform” rating in a report on Tuesday, January 6th. Mizuho set a $15.00 price objective on Fortrea in a report on Friday, January 9th. Finally, Citigroup upgraded Fortrea from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $12.00 to $21.00 in a research report on Thursday, December 11th. Four investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $16.15.

Fortrea Stock Performance

NASDAQ FTRE opened at $10.72 on Friday. The firm has a market cap of $990.53 million, a P/E ratio of -0.98, a P/E/G ratio of 0.33 and a beta of 1.59. Fortrea has a 52-week low of $3.97 and a 52-week high of $18.67. The business’s 50-day moving average price is $15.14 and its 200 day moving average price is $12.34. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 1.81.

Fortrea (NASDAQ:FTRE) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.07). The company had revenue of $660.50 million for the quarter, compared to analyst estimates of $665.22 million. Fortrea had a positive return on equity of 5.97% and a negative net margin of 36.21%. On average, equities research analysts expect that Fortrea will post 0.51 earnings per share for the current year.

Institutional Investors Weigh In On Fortrea

A number of hedge funds and other institutional investors have recently modified their holdings of FTRE. Royal Bank of Canada boosted its stake in shares of Fortrea by 48.9% during the 1st quarter. Royal Bank of Canada now owns 121,707 shares of the company’s stock worth $920,000 after acquiring an additional 39,944 shares in the last quarter. Caxton Associates LLP acquired a new position in Fortrea during the first quarter worth $196,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Fortrea by 10.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 282,780 shares of the company’s stock worth $2,135,000 after purchasing an additional 27,746 shares in the last quarter. Focus Partners Wealth acquired a new stake in Fortrea in the first quarter valued at $80,000. Finally, Acadian Asset Management LLC acquired a new stake in Fortrea in the first quarter valued at $65,000.

Fortrea News Summary

Here are the key news stories impacting Fortrea this week:

• Positive Sentiment: Management said full‑year revenue and adjusted EBITDA delivered in line with targets and that full‑year cost savings exceeded prior targets — a reassurance on operational execution. Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance
• Positive Sentiment: Robert W. Baird kept an “outperform” rating and a $16 price target (implying ~49% upside vs. current levels), signaling some analysts remain bullish on the company’s longer‑term outlook. Baird price target note
• Neutral Sentiment: Several full transcripts and earnings‑call highlights were published (useful for parsing management commentary and client/contract trends), giving investors primary‑source detail on drivers and margin dynamics. Fortrea Holdings Inc (FTRE) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Analyst coverage remains active — a recent Benzinga roundup reviews seven ratings, which can amplify volatility as differing views are disseminated. Deep Dive Into Fortrea Holdings Stock: Analyst Perspectives (7 Ratings)
• Negative Sentiment: Q4 results missed consensus: reported EPS $0.09 vs. $0.16 expected, and revenue $660.5M vs. ~$665M expected — the headline misses are driving the immediate negative reaction. Fortrea Q4 Earnings and Revenues Lag Estimates (Zacks)
• Negative Sentiment: Barclays cut its price target to $12 and set an “equal weight” rating — a formal shift toward neutrality/less bullishness that can pressure sentiment and weaken near‑term buyer conviction. Barclays price target cut
• Negative Sentiment: FY‑2026 revenue guidance was given in a range (~$2.6B–$2.7B), which sits slightly below consensus at the top end — the cautious top‑line outlook and an unclear EPS guide left some investors wanting more upside visibility. Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance

Fortrea Company Profile

Fortrea, Inc is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific’s Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company’s comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.

Fortrea’s core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services.